Trump Proposes 100% Tariff on Imported Generic Drugs Starting August 2028

President Trump has proposed a phased tariff plan that will impose a 100% tariff on imported generic drugs starting in August 2028. This initiative is contingent upon manufacturers relocating their production to the U.S. The announcement has already influenced stock prices of several generic drug manufacturers, reflecting market apprehension regarding the impending changes.

The tariff plan gives drugmakers until August 2028 to adjust their production strategies, creating a timeline for companies to respond to the new economic landscape. The U.S. imported pharmaceutical products valued at approximately $213 billion in 2025, highlighting the scale of the market affected by this decision.

Generic medicines account for over 90% of prescriptions in the U.S. but represent less than 13% of prescription-drug spending. This disparity underscores the importance of generic drugs in the healthcare system and the potential impact of the proposed tariffs. India, the largest exporter of generic drugs to the U.S., had exports valued at about $9.7 billion in 2025, making it a key player in this market.

The announcement comes amid ongoing supply disruptions in the U.S. generic drug market, which have been exacerbated by plant closures and quality issues. As the U.S. government seeks to reshore pharmaceutical production, the implications for international trade and domestic manufacturing will be significant.

As the implementation date approaches, companies will need to navigate the complexities of shifting production while addressing potential cost increases and supply chain disruptions. The long-term impact on drug prices and availability remains uncertain, but the tariff plan could reshape the landscape of generic drug manufacturing in the U.S. market.

Stakeholders should monitor stock market reactions from generic drug manufacturers as the tariff deadline approaches. Additionally, potential legislative or executive actions may clarify or alter the tariff implementation, further influencing the market dynamics.